Affiliation:
1. Sechenov First Moscow State Medical University
Abstract
Aim To compare serum concentrations of tryptophane (Trp) and its metabolites in subjects with no cardiovascular disease (CVD) and patients with СVD, including arterial hypertension (AH) and ischemic heart disease (IHD).Material and methods This study included 131 participants; 58 participants (11 of them with documented peripheral atherosclerosis) were included into the AH group, 46 participants were included into the IHD group, and 27 participants with no signs of CVD were included into the control group. Plasma concentrations of Trp and its metabolites were measured by high-performance liquid chromatography in combination with a triple quadrupole analyzer.Results Comparison of the three study groups revealed significant differences in concentrations of Trp (р=0.029), kynurenine (p<0.001), kynurenine/Trp ratio (p<0.001), quinolinic acid (р=0.007), kynurenic acid (р=0.003), serotonin (p<0.001), and 5‑hydroxyindoleacetic acid (5‑HIAA) (р=0.011). When the AH group was subdivided into subgroups without and with documented peripheral atherosclerosis, the intergroup differences remained for concentrations of kynurenine, kynurenine/Trp ratio, quinolinic acid, kynurenic acid, serotonin, and 5‑HIAA. Also, correlations were found between concentrations of Trp metabolites and laboratory and instrumental data, primarily inflammatory markers. Conclusion Analysis of serum concentrations of Trp and its metabolites in CVD patients showed increases in kynurenine, kynurenine/Trp ratio, quinolinic acid, kynurenic acid, and 5‑HIAA along with decreases in concentrations of Trp and serotonin in the groups of AH, AH with documented peripheral atherosclerosis, and IHD.
Publisher
APO Society of Specialists in Heart Failure
Subject
Cardiology and Cardiovascular Medicine
Reference25 articles.
1. Nitz K, Lacy M, Atzler D. Amino Acids and Their Metabolism in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(3):319–30. DOI: 10.1161/ATVBAHA.118.311572.
2. Anti-inflammatory therapy with kanakinumab for the treatment of atherosclerosis-related diseases: results of a double-blind placebo-controlled study CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study). Evidence-based Cardiology. 2017;10(3):11–6.
3. Lutgens E, Atzler D, Doring Y, Duchene J, Steffens S, Weber C. Immunotherapy for cardiovascular disease. European Heart Journal. 2019;40(48):3937–46. DOI: 10.1093/eurheartj/ehz283.
4. Getsina M.L., Chernevskaya E.A., Beloborodova N.V. The role of human and microbial metabolites of triptophane in severe diseases and critical ill (review). Journal of Clinical Practice. 2020;11(1):92–102.
5. Wei J, Zhang Z, Du Y, Yang X, Zhao L, Ni P et al. A combination of neuroimaging and plasma metabolomic analysis suggests inflammation is associated with white matter structural connectivity in major depressive disorder. Journal of Affective Disorders. 2022;318:7–15. DOI: 10.1016/j.jad.2022.08.108.